Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
136.5 EUR | +0.19% | -1.90% | -3.56% |
06-28 | Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial | MT |
06-28 | J&J Unit's Rybrevant Combo Gets EU Approval | MT |
Sales 2024 * | 88.75B 82.86B 121B | Sales 2025 * | 92.26B 86.14B 126B | Capitalization | 352B 328B 481B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 3.96 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.81 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
3.3% | Yield 2025 * |
3.45% | Free-Float | 77.08% |
Latest transcript on Johnson & Johnson
1 week | -1.90% | ||
Current month | +0.86% | ||
1 month | +2.65% | ||
3 months | -7.30% | ||
6 months | -3.56% | ||
Current year | -3.56% |
Managers | Title | Age | Since |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 88-12-31 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 97-12-31 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 19-11-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 19-04-24 |
D. Davis
BRD | Director/Board Member | 72 | 14-06-18 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 09-10-21 |
Date | Price | Change |
---|---|---|
24-06-28 | 136.5 | +0.19% |
24-06-27 | 136.2 | -0.83% |
24-06-26 | 137.3 | -0.04% |
24-06-25 | 137.4 | -1.05% |
24-06-24 | 138.9 | -0.17% |
Delayed Quote Börse Stuttgart, June 28, 2024 at 03:01 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
+44.05% | 641B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B | |
+0.20% | 120B |
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock